Ardelyx inc (ARDX) - News Archive

WALTHAM, Mass. March 31, 2025 Ardelyx, Inc. (Nasdaq: ARDX), a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative first-in-class medicines, has exciting news...

Ardelyx Inc has recently provided an update that illuminates its evolving commercial landscape and strategic priorities, aimed at enhancing its position within the pharmaceutical industry. Following a notable ascent in...

: Ardelyx, Inc. a biopharmaceutical company recognized for its innovative approaches in addressing critical unmet medical needs, recently announced their plan to present additional data on XPHOZAH (tenapanor) at the Ame...

In an era where healthcare innovation is paramount, Ardelyx, Inc. a biopharmaceutical entity based in Waltham, Massachusetts, has recently made strides in addressing a critical gastrointestinal disorder—irritable bowel...

In a timely announcement, the Rosen Law Firm, recognized as a leading global counsel specializing in investor rights, has urged investors of Ardelyx, Inc. (NASDAQ: ARDX) to take swift and decisive action ahead of the im...

Important Notice for Ardelyx, Inc. Investors Regarding Class Action Securities LawsuitThe securities market, while offering significant opportunities for investors, is perpetually riddled with risks, particularly when m...

Ardelyx, Inc. a biopharmaceutical company specializing in the development of innovative therapies for patients with gastrointestinal and kidney conditions, is currently navigating turbulent waters. Recent reports have h...

In the dynamic landscape of financial markets, investor confidence is often swayed by the performance metrics of companies and their legal standings. Ardelyx, Inc. (NASDAQ: ARDX), a biopharmaceutical company, currently...

In an exciting development for patients with chronic kidney disease (CKD) undergoing dialysis, Ardelyx, Inc. (Nasdaq: ARDX), a pioneering biopharmaceutical company, has announced the publication of two plain language su...

This article aims to analyze Ardelyx Inc s recent performance in light of several news articles published between June 27 and July 4, 2024. By examining the content of these articles, we will assess how the market has r...

Ardelyx, Inc. Continues to Grant Employment Inducement Options and RSUs to New Non-Executive EmployeesArdelyx, a leading biopharmaceutical company focused on developing innovative medicines, has been making waves in the...

In recent years, hyperphosphatemia, a condition characterized by abnormally high levels of phosphate in the blood, has become an increasingly prevalent and challenging issue within the healthcare industry. High phosphat...

Ardelyx, Inc. Empowers New Talent with Substantial Employment Inducement Grants WALTHAM, Mass., May 14, 2024 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical firm dedicated to the discovery, development, and commerci...

Ardelyx, a biopharmaceutical company dedicated to developing groundbreaking medicines for unmet medical needs, has announced the appointment of Mike Kelliher as the Executive Vice President of Corporate Development and...

In a dynamic and competitive industry like pharmaceuticals, attracting and retaining top-notch talent is crucial for continued success. To this end, Ardelyx, Inc., a prominent biopharmaceutical company, recently announc...

WALTHAM, Mass., Dec. 20, 2023 - Ardelyx, Inc. (Nasdaq: ARDX), a leading biopharmaceutical company dedicated to discovering, developing, and commercializing innovative, first-in-class medicines to address significant unm...

Ardelyx Employs Stock Options and RSUs to Enlist Top Talent, Intensifying the Quest for Medical BreakthroughsWALTHAM, Mass., Nov. 21, 2023 – Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company dedicated to discove...

WALTHAM, Mass., Nov. 13, 2023 - Ardelyx, Inc. (Nasdaq: ARDX), a renowned biopharmaceutical company committed to discovering, developing, and commercializing innovative, first-in-class medicines to address unmet medical...

WALTHAM, Mass., Sept. 07, 2023 - Ardelyx, Inc. (Nasdaq: ARDX), a leading biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines that address critical unmet medical needs...